Cargando…

C‐C Motif Chemokine Receptor 9 Exacerbates Pressure Overload–Induced Cardiac Hypertrophy and Dysfunction

BACKGROUND: Maladaptive cardiac hypertrophy is a major risk factor for heart failure, which is the leading cause of death worldwide. C‐C motif chemokine receptor 9 (CCR9), a subfamily of the G protein–coupled receptor supergene family, has been highlighted as an immunologic regulator in the developm...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xu, Zhengxi, Mei, Fanghua, Liu, Hanning, Sun, Cheng, Zheng, Zhe
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2016
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4889199/ https://www.ncbi.nlm.nih.gov/pubmed/27146447 http://dx.doi.org/10.1161/JAHA.116.003342

Ejemplares similares

C-C chemokine receptor 5 signaling contributes to cardiac remodeling and dysfunction under pressure overload
por: Wang, Xiaomin, et al.
Publicado: (2021)

Nicotinamide Riboside Alleviates Cardiac Dysfunction and Remodeling in Pressure Overload Cardiac Hypertrophy
por: Ma, Sai, et al.
Publicado: (2021)

Loss of Akap1 Exacerbates Pressure Overload-Induced Cardiac Hypertrophy and Heart Failure
por: Schiattarella, Gabriele G., et al.
Publicado: (2018)

Microtubule Stabilization in Pressure Overload Cardiac Hypertrophy
por: Sato, Hiroshi, et al.
Publicado: (1997)

Diet-induced obesity promotes altered remodeling and exacerbated cardiac hypertrophy following pressure overload
por: Holzem, Katherine M, et al.
Publicado: (2015)

miR-21 upregulation exacerbates pressure overload-induced cardiac hypertrophy in aged hearts
por: Chang, Wei-Ting, et al.
Publicado: (2022)

The Natural Product Zerumbone Suppresses Pressure Overload-Induced Cardiac Dysfunction by Inhibiting Cardiac Hypertrophy and Fibrosis
por: Tojima, Mikuto, et al.
Publicado: (2021)

Combination of C-X-C motif chemokine 9 and C-X-C motif chemokine 10 antibodies with FTY720 prolongs the survival of cardiac retransplantation allografts in a mouse model
por: MA, TENG, et al.
Publicado: (2015)

Wnt-C59 Attenuates Pressure Overload-Induced Cardiac Hypertrophy via Interruption of Wnt Pathway
por: Zhao, Zhengbo, et al.
Publicado: (2020)

Bezafibrate Attenuates Pressure Overload-Induced Cardiac Hypertrophy and Fibrosis
por: Xu, Si-Chi, et al.
Publicado: (2017)

Iron overload exacerbates age-associated cardiac hypertrophy in a mouse model of hemochromatosis
por: Sukumaran, Abitha, et al.
Publicado: (2017)

Activating Transcription Factor 3 Deficiency Promotes Cardiac Hypertrophy, Dysfunction, and Fibrosis Induced by Pressure Overload
por: Zhou, Heng, et al.
Publicado: (2011)

Celecoxib prevents pressure overload‐induced cardiac hypertrophy and dysfunction by inhibiting inflammation, apoptosis and oxidative stress
por: Zhang, Chi, et al.
Publicado: (2015)

Sanggenon C protects against pressure overload-induced cardiac hypertrophy via the calcineurin/NFAT2 pathway
por: Xiao, Lili, et al.
Publicado: (2017)

Pressure overload promotes cystatin C secretion of cardiomyocytes to regulate the MAPK signaling pathway and mediate cardiac hypertrophy
por: Shen, Yi, et al.
Publicado: (2020)

Retracted: Wnt-C59 Attenuates Pressure Overload-Induced Cardiac Hypertrophy via Interruption of Wnt Pathway
por: Zhao, Zhengbo, et al.
Publicado: (2023)

Cardiac Expression of Factor X Mediates Cardiac Hypertrophy and Fibrosis in Pressure Overload
por: Guo, Xinji, et al.
Publicado: (2020)

Cardiac Expression of Factor X Mediates Cardiac Hypertrophy and Fibrosis in Pressure Overload
Publicado: (2022)

IKKi Deficiency Promotes Pressure Overload-Induced Cardiac Hypertrophy and Fibrosis
por: Dai, Jia, et al.
Publicado: (2013)

Intermedin Suppresses Pressure Overload Cardiac Hypertrophy through Activation of Autophagy
por: Chen, HuaLi, et al.
Publicado: (2013)

Effects of miRNA-455 on cardiac hypertrophy induced by pressure overload
por: WU, CHUNTAO, et al.
Publicado: (2015)

Innate Immune Cells in Pressure Overload-Induced Cardiac Hypertrophy and Remodeling
por: Liu, Xin, et al.
Publicado: (2021)

Endothelial mineralocorticoid receptor contributes to systolic dysfunction induced by pressure overload without modulating cardiac hypertrophy or inflammation
por: Salvador, Ane M., et al.
Publicado: (2017)

Sacubitril/valsartan ameliorates cardiac hypertrophy and preserves diastolic function in cardiac pressure overload
por: Nordén, Einar Sjaastad, et al.
Publicado: (2021)

Chemokine (C-C Motif) Ligand 2/Chemokine Receptor 2 (CCR2) Axis Blockade to Delay Chondrocyte Hypertrophy as a Therapeutic Strategy for Osteoarthritis
por: Wang, Zidong, et al.
Publicado: (2021)

The role of androgens in pressure overload myocardial hypertrophy
por: Schafstedde, Marie, et al.
Publicado: (2023)

Epigallocatechin-3 gallate prevents cardiac hypertrophy induced by pressure overload in rats
por: Hao, Jia, et al.
Publicado: (2007)

Augmented Cardiac Hypertrophy in Response to Pressure Overload in Mice Lacking ELTD1
por: Xiao, Jinfeng, et al.
Publicado: (2012)

MicroRNA-327 regulates cardiac hypertrophy and fibrosis induced by pressure overload
por: Ji, Yue, et al.
Publicado: (2018)

Protective Roles of Interferon‐γ in Cardiac Hypertrophy Induced by Sustained Pressure Overload
por: Kimura, Akihiko, et al.
Publicado: (2018)

Rutaecarpine Ameliorates Pressure Overload Cardiac Hypertrophy by Suppression of Calcineurin and Angiotensin II
por: Li, Shujun, et al.
Publicado: (2021)

Peroxiredoxin-5 Knockdown Accelerates Pressure Overload-Induced Cardiac Hypertrophy in Mice
por: Hu, Chengyun, et al.
Publicado: (2022)

Eosinophils protect pressure overload- and β-adrenoreceptor agonist-induced cardiac hypertrophy
por: Yang, Chongzhe, et al.
Publicado: (2022)

Ganoderma lucidum polysaccharides attenuates pressure-overload-induced pathological cardiac hypertrophy
por: Zhen, Changlin, et al.
Publicado: (2023)

Plasma levels of monokine induced by interferon-gamma/chemokine (C-X-X motif) ligand 9, thymus and activation-regulated chemokine/chemokine (C-C motif) ligand 17 in children with Kawasaki disease
por: Feng, Siqi, et al.
Publicado: (2015)

Postnatal Ablation of Foxm1 from Cardiomyocytes Causes Late Onset Cardiac Hypertrophy and Fibrosis without Exacerbating Pressure Overload-Induced Cardiac Remodeling
por: Bolte, Craig, et al.
Publicado: (2012)

IL-12α deficiency attenuates pressure overload-induced cardiac inflammation, hypertrophy, dysfunction, and heart failure progression
por: Bhattarai, Umesh, et al.
Publicado: (2023)

Effects of Estrogen, an ERα Agonist and Raloxifene on Pressure Overload Induced Cardiac Hypertrophy
por: Westphal, Christina, et al.
Publicado: (2012)

Electrophysiological characteristics of pressure overload-induced cardiac hypertrophy and its influence on ventricular arrhythmias
por: Chen, Xiaowei, et al.
Publicado: (2017)

Anacardic acid attenuates pressure‐overload cardiac hypertrophy through inhibiting histone acetylases
por: Li, Shuo, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_r4f5a85l10rbc0pjnodbpgjkkh